EUVIMEDEUVIMED entdecken
Crossref

Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with ESKD

Steph Karpinski iD, Rizwan Qazi, Terrence Bjordahl, Scott Sibbel, Eric Weinhandl iD, Francesca Tentori, Steven M Brunelli

Clinical Journal of the American Society of Nephrology · 2026-11 · 21 (11) · 1928-1935

DOI: 10.2215/cjn.0000001208 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 25.08.2026. Verfasst von Steph Karpinski und 6 weiteren Autor:innen. Beteiligte Einrichtung: DaVita, Inc., Denver, Colorado. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Hospitalization, Kidney Failure, Chronic, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Glucagon-like peptide-1 receptor agonist have shown clinical benefits in patients with chronic kidney disease, but there are no randomized trials to support their efficacy in ESKD. This matched retrospective cohort study used electronic health record from a dialysis provider and was conducted in diabetic, incident in-center hemodialysis patients. Results indicated that continued use of glucagon-like peptide-1 receptor agonist is associated with a 9% lower hospitalization and a 17% lower mortality rate.

Background

The recent clinical trial FLOW showed that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), reduced the risk of clinical outcomes and death from cardiovascular causes in patients with CKD and type 2 diabetes. Given the substantial benefit to patients with CKD, the question remains whether these drugs benefit patients with ESKD. We sought to evaluate the impact of GLP-1 RA use in patients with incident ESKD on clinical outcomes.

Methods

Patients included in this matched retrospective cohort study were adult patients with ESKD who initiated thrice-weekly in-center hemodialysis at a kidney care organization between January 2018 and April 2024. Using internal electronic health record data, eligible patients who initiated dialysis on a GLP-1 RA (with evidence of a GLP-1 RA prescription in the first 30 days after dialysis initiation; n =2492) were matched 1:1 to those not on a prescription. Patients were followed from index date until death or the end of the study (July 31, 2024). Incident rate ratios were estimated using a negative binomial distribution with a random intercept to account for the matched nature of the data.

Results

Patients with a GLP-1 RA prescription in the first month of dialysis had a mean±SD age of 63±12 years and were predominately male (59%). Compared with other eligible dialysis patients, nearly all patients on a GLP-1 RA had a known diagnosis of diabetes (98% versus 73%), a majority had evidence of predialysis nephrology care (76% versus 67%), were of White race (46% versus 39%), and had a mean±SD body mass index of 33±8 kg/m 2 (versus 30±8). After matching and adjustment, GLP-1 RAs were independently associated with lower hospitalization (incidence rate ratios, 0.91 [0.87 to 0.96]) and mortality (Incidence rate ratios, 0.83 [0.73 to 0.95]) rates.

Conclusions

Among incident in-center hemodialysis patients, GLP-1 RA use was independently associated with a 9% lower hospitalization rate and a 17% lower mortality rate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsHospitalizationKidney Failure, ChronicHypoglycemic AgentsHumansFemaleRetrospective StudiesMaleMiddle AgedAgedSemaglutideRenal DialysisRisk AssessmentGlucagon-Like Peptides

Stichwörter der Autor:innen

ESKDGLP-1 receptor agonistsdialysis

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsSemaglutideHypoglycemic AgentsGlucagon-Like Peptides

Autor:innen und Institutionen

  • DaVita, Inc., Denver, Colorado.
  • Kidney Specialists of Southern Nevada, Las Vegas, Nevada.
  • Division of Nephrology, Department of Medicine, University of Utah, Salt Lake City, Utah.
  • Department of Pharmaceutical Care and Health Systems, University of Minnesota, Minneapolis, Minnesota.

ORCID-Profile: Steph Karpinski, Eric Weinhandl

Zitieren

APA

Karpinski, S., Qazi, R., Bjordahl, T., Sibbel, S., Weinhandl, E., Tentori, F., & Brunelli, S. M. (2026). Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with ESKD. Clinical Journal of the American Society of Nephrology, 21(11), 1928-1935. https://doi.org/10.2215/cjn.0000001208

Vancouver

Karpinski S, Qazi R, Bjordahl T, Sibbel S, Weinhandl E, Tentori F, et al. Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with ESKD. Clinical Journal of the American Society of Nephrology. 2026;21(11):1928-1935. doi:10.2215/cjn.0000001208

BibTeX
@article{Karpinski2026,
  author = {Karpinski, Steph and Qazi, Rizwan and Bjordahl, Terrence and Sibbel, Scott and Weinhandl, Eric and Tentori, Francesca and Brunelli, Steven M},
  title = {Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with ESKD},
  journal = {Clinical Journal of the American Society of Nephrology},
  year = {2026},
  volume = {21},
  number = {11},
  pages = {1928--1935},
  doi = {10.2215/cjn.0000001208}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche